| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), ELTX's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 186.9K | - | - | |
| Other | 64.6K | - | - | |
| Other | 60.8K | - | - | |
| Other | 52.8K | - | - | |
| Dir | 21.8K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 22, 2023 | Chudnovsky Yekaterina | Director, 10% Owner | Buy | 1,213,000 | $5.81 | $7,047,530.00 | +172.6% | +2.3% | -24.3% | |
| May 25, 2022 | Venkatesan Jay | See Remarks | Buy | 11,313 | $1.25 | $14,102.79 | +0.6% | -19.8% | -32.5% | |
| May 24, 2022 | Venkatesan Jay | See Remarks | Buy | 82,200 | $1.23 | $101,428.00 | +5.0% | -17.9% | -33.3% | |
| May 20, 2022 | Nissenson Allen | Director | Buy | 9,383 | $1.16 | $10,925.02 | New | -20.3% | -38.3% | |
| Dec 28, 2021 | Venkatesan Jay | See Remarks | Buy | 277,244 | $2.63 | $730,373.17 | +20.4% | -17.0% | -67.6% | |
| Dec 20, 2021 | Neylan John F.95 | See Remarks | Sell | 358 | $2.62 | $938.00 | -1.0% | -17.6% | -68.1% | |
| Dec 20, 2021 | Venkatesan Jay | See Remarks | Buy | 3,527 | $2.54 | $8,975.86 | +0.3% | -17.6% | -68.1% | |
| Dec 17, 2021 | Venkatesan Jay | See Remarks | Buy | 41,625 | $2.55 | $105,951.18 | +3.2% | -12.5% | -66.7% | |
| Dec 15, 2021 | Curhan Gregory S | See Remarks | Buy | 4,000 | $2.37 | $9,480.00 | New | -29.3% | -66.3% | |
| Dec 15, 2021 | Venkatesan Jay | See Remarks | Buy | 77,604 | $2.41 | $186,955.80 | +6.3% | -29.3% | -66.3% |